So, we are quite excited about that. And I think we can feel that when you talk about macroeconomics from us. And as for the currency, maybe J.J. has got some insight on that.
J.J. Pellegrino: So, I will try and make it sequential here I guess, in a way because it is turning on us in terms of the dollar weakening. But in Q4, the FX hurt us year-over-year for about $1.7 million reduction in sales. And then for the full year last year, it was like $6.2 million, something like that. And then in Q1 of this year, €˜23, maybe it’s a $1.1 million or so bad guy year-over-year. But then Brooks starts to change as last year’s rate came down and this year’s rates starting to go up, those two are starting to cross. And so when you get into Q3, it starts to be a help year-over-year. And by the end of the year, you are kind of neutral in 2023. So, you can sort of not think about FX for the full year 2023.
Brooks O’Neil: Great guys. Thanks a lot.
George LeMaitre: Thanks a lot Brooks.
Operator: Thank you. Our next question comes from Jim Sidoti from Sidoti. Your line is now open.
Jim Sidoti: Hi. Good afternoon guys. Thanks for taking the question. I am looking back over the last 5 years or 6 years, and you have never grown Q1 $2 million now off of Q4 the prior year before. Is that related to the backlog for Omniflow?
George LeMaitre: No, it’s not precisely related to that. That’s not that large of a factor. It’s some of it in there. But no, we just feel like it’s a very good quarter. And you are right to pick up the sequential cadence. It’s pretty rare that, that happens. I am glad you are following us that closely that you are watching that.
Jim Sidoti: Okay. What exactly happened with Omniflow and how material is that?
George LeMaitre: Sure. So, Omniflow is approximately a $5.5 million product when it’s running correctly. In the transition from Melbourne, we used to make it there and now we make it in Burlington. In that transition, we messed up the transfer and some of the qualifications didn’t work out. We kind of got it started in Q3, and we hit a little bit of a speed bump with some of the sterilization validations. Those had now been sorted out as of January, and we are shipping to our €“ it’s mostly European product, Jim. So, we are shipping to our European headquarters right now. And we are actually selling devices now. So, we have broken through, it was basically a shutout for November and December, and we have indeed broken through that now and we are selling.
But so $5.5 million product line in a great quarter, what does that mean it’s selling $1.75 million or something a quarter. And I think in Q4, if I remember correctly from the charts I was seeing, we sold about $700,000, $600,000 worth of it. So, we still have to catch up to that and then go a little further. So, that’s why it isn’t such a big difference between Q4 2022 and Q1 2023, because we did sell stuff in October. And now we are going to €“ sort of February and March, we are going to be selling stuff against that October sales. So, not exactly because of that, it’s a good quarter. We don’t exactly understand why it’s such a good quarter. Maybe some of the hospital staffing comments I was making to the last question from Brooks sort of an indication of what one of our hypotheses.
We also have a pretty robust price hike on one of our valvulotomes product lines called easy sight , which has always been sort of priced as a junior valvulotome option and now it’s priced exactly at parity with the regular valvulotome. So, we got a little price hike thing there, which may be a nice difference between Q4 and Q1 as well.
